BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38206300)

  • 21. Identification of potential crucial genes associated with the pathogenesis and prognosis of liver hepatocellular carcinoma.
    Shi L; Shang X; Nie K; Lin Z; Zheng M; Wang M; Yuan H; Zhu Z
    J Clin Pathol; 2021 Aug; 74(8):504-512. PubMed ID: 33004423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High expression of RNF31 is associated with tumor immune cell infiltration and leads to poor prognosis in liver hepatocellular carcinoma.
    Xi G; Cheng R; Liang L; Che N; Wang Y; Zhao N; Liang X; Shao B; Zhao X; Zhang D
    Sci Rep; 2023 Apr; 13(1):6957. PubMed ID: 37117215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic significance and carcinogenic mechanism of pan-cancer gene POU5F1 in liver hepatocellular carcinoma.
    He D; Zhang X; Tu J
    Cancer Med; 2020 Dec; 9(23):8782-8800. PubMed ID: 32978904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multi-omics analysis reveals the involvement of origin recognition complex subunit 6 in tumor immune regulation and malignant progression.
    Zhu J; Chen Q; Zeng L; Gao H; Wu T; He Y; Xu J; Pang J; Peng J; Deng Y; Han Y; Yi W
    Front Immunol; 2023; 14():1236806. PubMed ID: 37901236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A disulfidptosis-related lncRNAs signature in hepatocellular carcinoma: prognostic prediction, tumor immune microenvironment and drug susceptibility.
    Liu Y; Meng J; Ruan X; Wei F; Zhang F; Qin X
    Sci Rep; 2024 Jan; 14(1):746. PubMed ID: 38185671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BUB1 predicts poor prognosis and immune status in liver hepatocellular carcinoma.
    Qi W; Bai Y; Wang Y; Liu L; Zhang Y; Yu Y; Chen H
    APMIS; 2022 Jul; 130(7):371-382. PubMed ID: 35255180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive analysis of diverse programmed cell death patterns in the prognosis, tumor microenvironment and drug sensitivity in hepatocellular carcinoma.
    Yu Y; Lou Y; Zhu J; Wang X
    Medicine (Baltimore); 2023 Dec; 102(48):e36239. PubMed ID: 38050240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of topoisomerase 2A as a novel bone metastasis-related gene in liver hepatocellular carcinoma.
    Feng J; Wei X; Liu Y; Zhang Y; Li G; Xu Y; Zhou P; Zhang J; Han X; Zhang C; Zhang Y; Wang G
    Aging (Albany NY); 2023 Nov; 15(22):13010-13040. PubMed ID: 37980167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma.
    Qiu C; Li Z; Cao W; Cai X; Ye L; Zhang C; Ma Y; Wang X; Yang Y
    Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34435618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of hepatocellular carcinoma-related subtypes and development of a prognostic model: a study based on ferritinophagy-related genes.
    Wang G; Li J; Zhu L; Zhou Z; Ma Z; Zhang H; Yang Y; Niu Q; Wang X
    Discov Oncol; 2023 Aug; 14(1):147. PubMed ID: 37555866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of MICALL1 and associates with immune infiltration in liver hepatocellular carcinoma patients.
    Yang Y; Zhao W; Du J; Wang Y
    Cancer Biomark; 2023; 37(3):147-160. PubMed ID: 37248888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. G6PD and machine learning algorithms as prognostic and diagnostic indicators of liver hepatocellular carcinoma.
    Li F; Wang B; Li H; Kong L; Zhu B
    BMC Cancer; 2024 Jan; 24(1):157. PubMed ID: 38297250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FANCI is Associated with Poor Prognosis and Immune Infiltration in Liver Hepatocellular Carcinoma.
    Hou Y; Li J; Yu A; Deng K; Chen J; Wang Z; Huang L; Ma S; Dai X
    Int J Med Sci; 2023; 20(7):918-932. PubMed ID: 37324186
    [No Abstract]   [Full Text] [Related]  

  • 34. Comprehensive Analysis on the Specific Role and Function of Mitochondrial Inner Membrane Protein MPV17 in Liver Hepatocellular Carcinoma.
    Tao H; Wang C; Lu C; Ma N; Zhu Y; Xuan S; Zhou X
    Genet Res (Camb); 2022; 2022():7236823. PubMed ID: 35919033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and validation of palmitoylation metabolism-related signature for liver hepatocellular carcinoma.
    Feng R; Cheng D; Chen X; Yang L; Wu H
    Biochem Biophys Res Commun; 2024 Jan; 692():149325. PubMed ID: 38056161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and in vitro and in vivo validation of the key role of GSDME in pyroptosis-related genes signature in hepatocellular carcinoma.
    Chen X; Yang M; Wang L; Wang Y; Tu J; Zhou X; Yuan X
    BMC Cancer; 2023 May; 23(1):411. PubMed ID: 37149620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of an immune-related prognostic index associated with hepatocellular carcinoma.
    Hu B; Yang XB; Sang XT
    Aging (Albany NY); 2020 Mar; 12(6):5010-5030. PubMed ID: 32191631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.
    Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H
    J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ANXA10 is a prognostic biomarker and suppressor of hepatocellular carcinoma: a bioinformatics analysis and experimental validation.
    Zhang C; Peng L; Gu H; Wang J; Wang Y; Xu Z
    Sci Rep; 2023 Jan; 13(1):1583. PubMed ID: 36709331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The integration of machine learning and multi-omics analysis provides a powerful approach to screen aging-related genes and predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
    Shen J; Gao H; Li B; Huang Y; Shi Y
    Aging (Albany NY); 2023 Jul; 15(14):6848-6864. PubMed ID: 37517087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.